Petrovax and Intellogic launch a project to use the Botkin.AI platform for studying the effect of Longidaze® among patients recovered from COVID-19
The joint project of Petrovax and Intellogic for testing the efficacy and safety of Longidaze® is the first in Russia and one of the first in the world. It applies artificial intelligence to determine the degree of lung damage on patients, including those recovered from COVID-19.
The multicenter observational study is aimed at assessing the efficacy and safety of the Longidaze® solution for preventing and treating pulmonary fibrosis – serious complication from the COVID-19 leading to respiratory failure. The study is organized in 14 clinical centers around Russia and Kazakhstan with the participation of 200 volunteers.
Longidaze includes a unique hyaluronidase enzyme capable of eliminating excess hyaluronic acid, preventing the formation of fibrous tissue in the lungs and contributing to a significant improvement in the general condition of patients, in particular those who have undergone coronavirus infection and suffer from respiratory failure1, 2, 3.
Botkin.AI measures the percentage of lung damage to tenths, allowing for maximally objective CT results, has a wide scope of applications, and can be used in clinical trials of medicine against coronavirus. The use of Botkin.AI will allow singling out key patients to whom this therapy will be most effective.
1 Shi Y. et al. COVID-19 infection: the perspectives on immune responses. – 2020
2 Mong M. A., Awkal J. A., Marik P. E. Systematic review of COVID-19 autopsies: accelerated hyaluronan concentration as the primary driver of morbidity and mortality in high-risk COVID-19 patients: with therapeutic introduction of an oral hyaluronan inhibitor in the prevention of “Induced Hyaluronan Storm” Syndrome //medRxiv. – 2020
3 Ding M. et al. Correlation analysis of the severity and clinical prognosis of 32 cases of patients with COVID-19 //Respiratory medicine. – 2020. – Т. 167